In 1993 Dr. Maksoud established Maksoud Pharm Inc., a chain of independent retail pharmacies in the tri-state area. Later, he launched Community Care Rx, Inc., a long-term care pharmacy opening for business in September 2010 to focus on serving the long-term care facilities in the 5 boroughs, Long Island and Westchester. In 2013 Community Care Rx celebrated the opening of A New Jersey location in the town of Totowa.
After Mr. Maksoud’s success with Community Care Rx, he opened Community Care Consulting which provides clinical expertise and services to a wide variety of healthcare settings by experienced consultant pharmacists. He is also the founder of Community Care Specialty Pharmacy which works with the entire health care ecosystem to connect patients who have chronic and rare conditions to medication, information and funding.
Mathew Cherian is currently retired from his position as Director and Senior Fellow at a Leading Pharmaceutical Company. He is a 34-year industry veteran with a significant track record in the pharmaceutical industry (US and Europe). Mathew oversaw leading early-stage development of products and coordinated his work between multiple worldwide sites of Pfizer. His expertise and experience in complex products is helping drive development of products in multiple therapeutic areas.
Mathew is an expert in drug/device combination products and leads efforts to develop Differentiated Drug Delivery systems, which are highly coveted value-added products.
Mathew holds a Ph.D. in chemical engineering from the University of Rhode Island, is an inventor and has several patents. He is recognized in the industry as a thought- leader, and regularly makes presentations on current topics. Mathew serves on the Executive Committee of International Pharmaceutical Society.
Mike is currently the owner of Snider Consultancy LLC a firm specializing in Acquisition Support, Business Valuations, and Litigation Support. Mike has held several designations during his career: CPA, CVA, CM&AA, and CGMA, as well as registered as a series 63, 7 and 79.
Prior experience includes Managing Director of Hunter Wise Financial Group, LLC, a mid-market Investment Bank and co-founding MSB, an int'l business consulting firm with offices in the United States of America and the United Kingdom. Additionally, Mike served in several senior financial positions within the International Life Segment of ACE Limited, an int'l insurance company (ACE); first as Chief Financial Officer and then as SVP, Global Operational Initiatives. Prior to ACE, Mike spent 22 years with Primerica, a group of wholly owned subsidiaries of Citigroup (now a publicly-held company). While at Primerica, Mike served in a number of capacities for most of the companies within the group; including Board Member, Executive Vice President, CFO, Controller, and Treasurer. During his tenure with Primerica, Mike led the company’s int'l expansion effort; established the company’s Acctg Department; participated in a principal role on several mergers, sophisticated financing arrangements, and corporate reorganization efforts; and, worked extensively with the attorneys of Primerica and Citigroup providing litigation support.
Prior to joining Primerica Mike was the Controller of a life insurance company and a member of the Audit Staff at two different national and int'l CPA firms. Mike began his career with Shell Oil in Houston, TX. He was also on the Advisory Boards of the AMAA and the Nanovic Institute for European Studies at the University of Notre Dame.
VP of Operations
Dr. Thomas Ingallinera is advisor to Dawah Pharmaceuticals. He provides technical support in pharmaceutics. Dr. Tom has over 40 years of experience in pharmaceutical development, with particular expertise in parenteral dosage forms. He has advised on product development programs across the continuum, from pre-formulation through commercial production. He has worked at several leading pharmaceutical companies including Pharmaceutics International, BioCryst Pharmaceuticals, Parenta Pharmaceuticals, AAI Pharma, Genzyme, Burroughs Wellcome, and A.H. Robins. Dr. Ingallinera has a B.S. in Pharmacy with a Ph.D. in Pharmaceutics from Virginia Commonwealth University. Dr. Tom also serves as a member of the Technical Advisory Group for the Bill and Melinda Gates Foundation.
Corporate Development, Founder
Nicholas Vartanian comes from a diverse background. Nicholas worked under the direction of the previous Mayor of Los Angeles, Antonio Villaraigosa, as an International Trade Analyst. During his tenure in the Mayor's office, Nicholas worked with Austin Beutner to acquire foreign direct investment dealing with investors such as Sheikh Mohammed bin Rashid al-Maktum of Dubai, previous Prime Minister of England Tony Blair, SVP of Forever 21 Christopher Lee, and assisted in securing a BYD electric car manufacturing plant in Los Angeles.
After leaving the public arena Nicholas joined The Luskin Center for Innovation, an economic think tank, where he co-authored a policy for a Feed-in-Tariff (FiT) taxation system for solar power on commercial rooftop properties. This was unanimously adopted by the City of Los Angeles and the Department of Water and Power. For the last 8 years, Nicholas has been working in the healthcare industry discovering effective ways to make changes within the industry holding executive positions within the pharmaceutical and clinical laboratory space.
Investor Relations, Founder
Founder and CEO of Lawandy Advisors, a corporate advisory firm focused on clients from small businesses to Fortune 1000 seeking strategic growth and valuation across all industry verticals. Prior to Diadem Capital, Stephen was a Director and Senior Corporate Banker at Citigroup covering both financial institutions and corporate Fortune 1000 clients within the Corporate and Investment Bank at Citi both here in the US and abroad. Stephen has held positions in relationship management, middle office, and operations. Stephen joined Citicorp/Citibank in loan operations in Delaware. He performed various functions within operations from secondary loan trading execution to a role as an agent of syndicated facilities. During this period, Stephen went on as a consultant for a foreign financial institution to help manage and implement a new loan portfolio to execute a capital markets transaction.
In late 1999, Stephen moved to New York City and took a position as a business analyst within Citigroup’s Global Derivatives Operations. Within the year, he worked with senior management on global reporting with various functions such as budgeting. In late 2000, Stephen joined the Global Subsidiaries Group North America relationship management team after which he became a Relationship Manager managing the overall Citigroup relationship for his European clients based in the US working alongside his various product partners. In 2007, Stephen was asked to move to Zurich, Switzerland where he was the Relationship Manager for Swiss-based consumer and industrial multinational corporations. In mid-2010, Stephen was asked and reassigned to manage a portfolio of financial institutions of foreign-based parents that operations in the US. His portfolio included all financial institutions based out of LATAM, Europe, the Middle East, Asia, Australia, and New Zealand. In 2013, the financial institution's team with Global Subsidiaries was spun out and now belongs within the Financial Institutions Group. He then has his role expanded to cover US-based Financial Institutions and Intermediaries.
Stephen received his Bachelor of Science degree in Finance with a minor in Economics from Rutgers University, School of Business.
Global Head of Sales and Marketing
Edward Finney is an experienced commercial executive with a command of strategic planning and tactical execution, resulting in maximized financial performance. He has held numerous senior organizational positions and has successfully launched numerous brands with pharmaceutical and medical services companies in multiple therapeutic areas and markets. Mr. Finney has been successful through a disciplined business approach which includes, but is not limited to, strong strategic planning, resolute financial oversight, an inspirational leadership style, putting in place key metrics to evaluate performance, and an unbridled focus on the customer, results, and profitability.
He is known as an innovative, visionary and collaborative leader who develops his senior managers and is an expert at launching new products and building commercial functions. Mr. Finney has successfully led organizations through 8 strategic transactions. He holds an MA in Management from Webster University and an MBA from the University of California, Irvine. Prior to his healthcare career, Ed was an Officer in the United States Army.